Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miransertib in Proteus Syndrome
NCT04316546Phase 2Active, not recruiting
- Sponsor
- National Human Genome Research Institute
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of miransertib in Proteus syndrome (PS), sponsored by National Human Genome Research Institute. Primary endpoint: Response Rate based on Change in Plantar CCTN Proportion. Started May 2022; status: active, not recruiting.
02
Drugs
miransertib
03
Conditions
Proteus syndrome (PS)
Beyond the preview
Go deeper on NCT04316546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316546.